Janssen presents new dermatology research at EADV 2016
The 25th Annual European Academy of Dermatology and Venerology (EADV) congress will be taking place in Vienna, Austria, from 28 September to 2 October. We are delighted that eight abstracts from our real-world evidence (RWE) studies and ongoing clinical trials programme in psoriasis and psoriatic arthritis (PsA) will be presented at the congress. RWE studies are of growing importance to clinicians as they provide information from a wide range of patients, allowing us to evaluate the effectiveness of treatments outside of the restrictions imposed on randomised clinical trials. This is relevant for psoriasis, as it is a chronic disease requiring lifelong treatment. Finding a tolerable and effective therapy that patients are happy to take in the long term is therefore of great importance.
Janssen is also pleased to be hosting a sponsored satellite symposium: ‘Psoriasis and IL-23: Building the evidence, focusing on the future’, which is taking place at 17:00–18:30 on Thursday 29 September. The symposium will look into the pathogenesis of psoriasis, how registry data can be used to inform long-term treatment decisions and the role of interleukin-23 in the inflammatory pathway.
The breath of data that is being shared at EADV demonstrates Janssen’s commitment to find new and better ways to prevent, intercept, treat and cure immune and inflammatory diseases, bringing transformative medicines to patient and health providers around the world.